ZNF468 Inhibitors

Chemical inhibitors of ZNF468 operate through various mechanisms to disrupt the protein's function in cellular signaling and transcriptional regulation. PD168393, an irreversible inhibitor of EGFR tyrosine kinase, disrupts signaling pathways that ZNF468 may regulate transcription in response to. This leads to the functional inhibition of ZNF468's role in these pathways. Similarly, Gefitinib targets EGFR, reducing the activity of downstream cascades that ZNF468 regulates, while SU5402 inhibits FGFR, disrupting fibroblast growth factor signaling pathways that ZNF468 may regulate. Y-27632 specifically inhibits the Rho/ROCK pathway, potentially essential for cytoskeletal organization and cellular functions that ZNF468 is implicated in through transcriptional regulation, resulting in the functional inhibition of ZNF468.

Furthermore, LY294002, by inhibiting PI3K, disrupts the PI3K/AKT pathway, critical for signaling pathways involving ZNF468, leading to its functional inhibition. U0126 inhibits MEK1/2, preventing the activation of the MAPK/ERK pathway, which ZNF468 may regulate. This results in the functional inhibition of ZNF468's transcriptional regulation activity within this pathway. SB431542, an inhibitor of the TGF-beta pathway, leads to the functional inhibition of ZNF468's regulatory role. SB203580, by inhibiting p38 MAPK, functionally inhibits pathways regulated by ZNF468. SP600125 inhibits the JNK pathway, which can result in the functional inhibition of ZNF468 if it is involved in transcriptional regulation mediated by JNK signaling. PP2 disrupts signaling pathways regulated by ZNF468 by inhibiting Src family kinases, leading to the functional inhibition of ZNF468's regulatory activity. Lastly, Rapamycin inhibits mTOR, disrupting its signaling pathway crucial for processes regulated by ZNF468, and WZ4003 inhibits NUAK family kinases, affecting pathways important for ZNF468 functions, leading to its functional inhibition.